{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"description":"DLTs: At least possibly drug-related AEs occurring during the first cycle of treatment and are:GR4 neutropenia \\>5 days/neutropenic fever;platelet count \\<10000mm\\^3 on \\>1 occasion;GR4 fatigue,or 2-point decline in ECOG performance status;\\>=GR3 nausea,diarrhea,and vomiting despite medical intervention;Any other clinically significant non-hematologic toxicity of \\>=GR3 considered not related to underlying MM;Any GR3/4 laboratory abnormality requiring hospitalization;dose interruption of either dasatinib and/or lenalidomide for \\>15 days due to any toxicity related to treatment with the combination.","groups":[{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 70 mg QD for 28 days and lenalidomide 15 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).","id":"OG000","title":"Dasatinib 70 mg + Lenalidomide 15 mg + Dexamethasone 40 mg"},{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 70 mg QD for 28 days and lenalidomide 20 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).","id":"OG001","title":"Dasatinib 70 mg + Lenalidomide 20 mg + Dexamethasone 40 mg"},{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 100 mg QD for 28 days and lenalidomide 20 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).","id":"OG002","title":"Dasatinib 100 mg + Lenalidomide 20 mg + Dexamethasone 40 mg"},{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 100 mg QD for 28 days and lenalidomide 25 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).","id":"OG003","title":"Dasatinib 100 mg + Lenalidomide 25 mg + Dexamethasone 40 mg"},{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 140 mg QD for 28 days and lenalidomide 25 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22). Cohort includes 4 participants treated for dose -finding phase and 13 participants treated in dose expansion phase.","id":"OG004","title":"Dasatinib 140 mg + Lenalidomide 25 mg + Dexamethasone 40 mg"}],"paramType":"NUMBER","populationDescription":"All treated participants, participants who received at least 1 dose of dasatinib. (Participants included from Cohort 5 are those involved in the dose escalation phase only.)","reportingStatus":"POSTED","timeFrame":"From the date of first dose until at least 30 days after the last dose of study drug (median duration of dasatinib treatment=5.2 months [range 0 to 33 months]).","title":"Number of Participants With Dose-limiting Toxicity (DLT)","type":"PRIMARY","unitOfMeasure":"participants"}